Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
08:00am, Monday, 29'th Jan 2024
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Wednesday, 24'th Jan 2024
Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pass
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Tuesday, 23'rd Jan 2024
From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
11:17am, Monday, 15'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 57.5% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questio
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
08:00am, Tuesday, 09'th Jan 2024
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
09:29pm, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
08:00am, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
LEXINGTON, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
Keros Therapeutics to Present at Upcoming Healthcare Conferences
08:00am, Tuesday, 07'th Nov 2023
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
08:00am, Monday, 06'th Nov 2023
LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
08:00am, Monday, 07'th Aug 2023
LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors.
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
08:00am, Monday, 12'th Jun 2023
LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
